Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML

被引：8
|
作者：
Fiedler, Walter [1 ]
Heuser, Michael [2 ]
Chromik, Joerg [3 ]
Thol, Felicitas [2 ]
Bokemeyer, Carsten [4 ]
Theile, Susann [5 ]
Lebkuechner, Isabell [5 ]
Kranich, Anne L. [6 ]
机构：
[1] Univ Hosp Eppendorf, Dept Hematol & Oncol, Hamburg, Germany
[2] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany
[3] Univ Hosp Frankfurt, Frankfurt, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Med Clin & Polyclin 2, Hamburg, Germany
[5] GSOmbH, Hamburg, Germany
[6] GSO Global B V, Amsterdam, Netherlands
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.341.341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
341
引用
收藏
页数：6
相关论文
共 50 条
  • [31] PHASE I STUDY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH FLUDARABINE AND CYTARABINE IN CHILDREN WITH RELAPSED OR REFRACTORY LEUKEMIA
    Alexander, Thomas
    Ribeiro, Raul
    Pounds, Stanley
    Lacayo, Norman
    Rubnitz, Jeffrey
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S10 - S10
  • [32] First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
    Razak, Albiruni R. A.
    Soerensen, Morten Mau
    Mahipal, Amit
    Shacham, Sharon
    Yau, Cindy Y. F.
    Lassen, Ulrik Niels
    McCauley, Dilara
    Cooksey, Jennifer
    Tan, David Shao Peng
    Saint-Martin, Jean-Richard
    Landesman, Yossi
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Mirza, Mansoor Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM)
    Chen, Christine I.
    Gutierrez, Martin
    Brown, Peter de Nully
    Gabrail, Nashat
    Baz, Rachid
    Reece, Donna E.
    Savona, Michael
    Trudel, Suzanne
    Siegel, David S.
    Mau-Sorensen, Morten
    Kuruvilla, John
    Byrd, John C.
    Shacham, Sharon
    Rashal, Tami
    Yau, Cindy Y. F.
    McCauley, Dilara
    Landesman, Yosef
    Klebanov, Boris
    Pond, Greg
    Oza, Amit M.
    Kauffman, Michael
    Mirza, Mansoor R.
    BLOOD, 2013, 122 (21)
  • [34] Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia
    Alexander, Thomas B.
    Lacayo, Norman J.
    Choi, John K.
    Ribeiro, Raul C.
    Pui, Ching-Hon
    Rubnitz, Jeffrey E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4094 - +
  • [35] Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma
    Cornell, Robert Frank
    Rossi, Adriana C.
    Baz, Rachid
    Hofmeister, Craig C.
    Shustik, Chaim
    Richter, Joshua R.
    Chen, Christine I.
    Vogl, Dan T.
    Baloglu, Erkan
    Senapedis, William
    Ellis, Joel
    Williams, Tony
    Shacham, Sharon
    Kauffman, Michael G.
    BLOOD, 2017, 130
  • [36] Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers
    Vergote, I.
    Lund, B.
    Havsteen, H.
    Ujmajuridze, Z.
    Van Nieuwenhuysen, E.
    Haslund, C.
    Juhler-Nottrup, T.
    Neven, P.
    Mau-Sorensen, M.
    Berteloot, P.
    Kranich, A.
    Rashal, T.
    Meade, J.
    Landesman, Y.
    Saint-Martin, J-R.
    Wright, G.
    Crochiere, M.
    Shacham, S.
    Kauffman, M.
    Mirza, M. Raza
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Results of a Phase 2 Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export (SINE) in 114 Patients With Gynaecological Cancers
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 8 - 10
  • [38] Results of a phase II trial of selinexor, an oral selective inhibitor of nuclear export (SINE), in patients with metastatic castration resistant prostate cancer (mCRPC) refractory to abiraterone or enzalutamide.
    Wei, Xiao
    Siegel, Adam Phillip
    Aggarwal, Rahul Raj
    Lin, Amy M.
    Friedlander, Terence W.
    Fong, Lawrence
    Paraganlija, Mirela
    Chang, Emily
    Zhang, Li
    Ryan, CharlesJ.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
    Abbey R. Sadowski
    Heather L. Gardner
    Antonella Borgatti
    Heather Wilson
    David M. Vail
    Joshua Lachowicz
    Christina Manley
    Avenelle Turner
    Mary K. Klein
    Angharad Waite
    Alexandra Sahora
    Cheryl A. London
    BMC Veterinary Research, 14
  • [40] Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma
    Tabe, Yoko
    Harada, Masako
    Miyamae, Yuka
    Kazuno, Saiko
    Fujimura, Tsutomu
    Ueno, Takashi
    Miida, Takashi
    Konopleva, Marina
    Andreeff, Michael
    BLOOD, 2014, 124 (21)
12345